Interstitial Brachytherapy. Low dose rate brachytherapy. Brachytherapy alone cures some cervical cancer. Learning Objectives

Similar documents

MRI Guided GYN Brachytherapy: Clinical Considerations

Challenging Cases in Cervical Cancer: Parametrial Boosting. Beth Erickson, MD, FACR, FASTRO Medical College Wisconsin

ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป

Outline - MRI - CT - US. - Combinations of imaging modalities for treatment planning

Basic Concepts in Image Based Brachytherapy (GEC-ESTRO Target Concept & Contouring)

Image guided brachytherapy in cervical cancer Clinical Aspects

Locally advanced disease & challenges in management

Basics of Cervix Brachytherapy. William Small, Jr., MD Professor and Chairman Loyola University Chicago

Johannes C. Athanasios Dimopoulos

Modern Interstitial GYN Brachytherapy. Conflicts: 8/3/2016. Modern Interstitial GYN Brachytherapy. 1. Use of MR

Definitions. Brachytherapy in treatment of cancer. Implantation Techniques and Methods of Dose Specifications. Importance of Brachytherapy in GYN

Patterns of Care in Patients with Cervical Cancer:

Venezia Advanced Gynecological Applicator Reaching beyond

EMBRACE- Studien Analysen und Perspektiven

Gyn Pre-planning: Intracavitary Insertion

Advances in Gynecologic Brachytherapy

Basics of Cervix Cancer Brachytherapy

The Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD

CT Guided Contouring: Challenges and Pitfalls

CT Guided Contouring: Challenges and Pitfalls

Image based Brachytherapy- HDR applications in Gynecological Tumors

INTRODUCTION PATIENT. J. Radiat. Res., 52, (2011)

ARROCase: Locally Advanced Endometrial Cancer

Brachytherapy in Africa

Recent Advances and current status of radiotherapy for cervix cancer

Linking DVH-parameters to clinical outcome. Richard Pötter, Medical University of Vienna, General Hospital of Vienna, Austria

GYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology

Image guided adaptive brachytherapy in patients with cervical cancer

Intracavitary + Interstitial Techniques Rationale

HHS Public Access Author manuscript Gynecol Oncol. Author manuscript; available in PMC 2018 May 01.

HDR Brachytherapy I: Overview of Clinical Application and QA. Disclosures. Learning Objectives 7/23/2014. Consultant, Varian Medical Systems

Staging and Treatment Update for Gynecologic Malignancies

Collection of Recorded Radiotherapy Seminars

The Evolution of RT Techniques for Gynaecological Cancers in a developing country context

Advancing Care Through Teamwork

HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee

Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE)

Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer

Course Directors : Teaching Staff : Guest Lecturer: Local Organiser: ESTRO coordinators: Melissa Vanderijst and Marta Jayes, project managers (BEL)

University of Kentucky. Markey Cancer Center

GYN GEC-ESTRO/ICRU 89 Target Concept. Richard Pötter Medical University Vienna

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

Gynecologic Vaginal Brachytherapy (Mostly Post-Op Endometrial)

University Cooperation Platform

Role of IMRT in the Treatment of Gynecologic Malignancies. John C. Roeske, PhD Associate Professor The University of Chicago

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC

Basic Fundamentals & Tricks of the Trade for Intracavitary Radiotherapy for Cervix Cancer. Paula A. Berner, B.S., CMD, FAAMD

3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER

Dosimetric comparison of interstitial brachytherapy with multi-channel vaginal cylinder plans in patients with vaginal tumors

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Management of Cervical Cancer in Resource Limited Settings

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE)

Dose-Volume Histogram Analysis in Point A-based Dose Prescription of High-dose-rate Brachytherapy for Cervical Carcinoma

Janjira Petsuksiri, M.D

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Role of MRI in Intracavitary Brachytherapy for Cervical Cancer: What the Radiologist Needs to Know

The New ICRU/GEC ESTRO Report in Clinical Practice. Disclosures

INTRODUCTION. J. Radiat. Res., 53, (2012)

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College

Original Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September Implementation Date: December 2014 Clinical Operations

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

Enterprise Interest None

External radiotherapy increases the risk of death from early stage endometrial cancer

Healthcare Professional Guide

Index. T1 and T2-weighted images, 189

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

presenting Brachytherapy with focus on Gynecological Cancers

NIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2015 July 01.

Brachytherapy Planning and Quality Assurance w Classical implant systems and modern computerized dosimetry w Most common clinical applications w

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

NEWER RADIATION (3 D -CRT, IMRT, IGRT) TECHNIQUES FOR CERVICAL CANCERS (COMMON PELVIC TUMORS)

Current Status of Image Guided Brachytherapy for Cervical Cancer In Japan

Brachytherapy Planning and Quality Assurance

Brachytherapy, Noncoronary

A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer

receive adjuvant chemotherapy

Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

Brachytherapy, Noncoronary

Palliative RT in Ovarian cancer

A Study on Dosimetry of Gynaecological Cancer and Quality Assurance of HDR Brachytherapy in BPKMCH, Nepal

Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix

TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY

Brachytherapy, Noncoronary

MR-Guided Brachytherapy

Use of imaging systems for patient modeling - PET and SPECT

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

Clinical Study Stereotactic Body Radiotherapy as an Alternative to Brachytherapy in Gynecologic Cancer

Brachytherapy an Overview

ART for Cervical Cancer: Dosimetry and Technical Aspects

HDR vs. LDR Is One Better Than The Other?

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

Country Presentations of FNCA FY2007 Workshop on Radiation Oncology

Clinical Implications Of Dose Summation And Adaptation

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning?

Transcription:

Interstitial Learning Objectives To discuss practical aspects of selection and insertion techniques for interstitial brachytherapy and their relation to clinical trials Akila Viswanathan, MD MPH Johns Hopkins Medicine January 29, 2017 Why brachytherapy? 57 of 199 inoperable cases cured treated between 1909-1913 Radium alone JAMA 1915 Pros Low dose rate brachytherapy Long half life Inexpensive Cs137 Stable 1-2 insertions Lower risk of normal tissue toxicity than HDR Sublethal damage repair Cons Radioactive safety Exposure to operator National safety Ir-192 shorter half life more frequent changes more expensive alone cures some cervical cancer ASCO Resource-Stratified Guideline Curative modality 50 years before Linac and chemotherapy Cytotoxic rather than cytostatic Cost-effective Bring curative treatment in underresourced environments Chuang et al 2016 1

combined with External beam improves survival is Necessary Tumor control probability correlated with RT dose and cervix ca volume Fletcher, Shukovsky J Radiol Electrol 56:383-400, 1975 4 y PC 4 y Survival Lanciano JROBP 20:95, 1991 Local Control Montana Cancer 57:148, 1986 External beam only 45% 19% External Beam + brachytherapy 67% 46% 40% 52% Overall Survival Overall survival by cervical cancer brachytherapy use 1998-2008 100 Propensity score-matched cohort 80 60 40 20 0 P <.001 No Years 25% reduction in brachytherapy; 13% reduction in survival Mul)variable Cox Regression Characteris)cs Cancer-Specific Survival Overall Survival HR (95% CI) P HR (95% CI) P No 1 (reference) 1 (reference) Yes 0.64 (0.57-0.71) <.001 0.66 (0.60-0.74) <.001 Stage IB2 1 (reference) 1 (reference) II 1.18 (0.93-1.49).17 1.16 (0.93-1.44).18 III 2.28 (1.80-2.88) <.001 2.14 (1.72-2.67) <.001 IVA 3.50 (2.49-4.92) <.001 3.08 (2.24-4.22) <.001 Histology SCC 1 (reference) 1 (reference) Adenocarcinoma 1.32 (1.10-1.60).004 1.28 (1.08-1.52).005 Other 1.26 (0.97-1.64).08 1.26 (0.98-1.60).07 Other significant factors: Age; Marital Status; Race; Ethnicity; Registry SEER, Int J Radiat Oncol Biol Phys 2013;87:111-119 Utilization of HDR increased from 13% to 70% LDR SBRT as a boost Node recurrence, sidewall recurrence Higher normal tissue dose Long term complication rate HDR HDR SBRT 1996-99 2005-07 IJROBP 2005;63(4):1083-92 IJROBP 2014;89(2):249-56 2

SBRT for Recurrent Cervix Ca Deodato et al. Oncol Repo 22:415-419 Dose 30 Gy/6 fractions 1 pt w vaginal recurrence Guckenerger et al. Failure 7/11 FAIL 2 Grade 4 fistulae 1 Grade 4 ileus Interstitial 50 Gy + 5 Gy x3 7/10 FAIL Rad onc 94:53-59 7 central recurrences Indications Indications for Interstitial Postop recurrence Recurrent endometrial cancer in vagina Extensive distal vaginal involvement from any ca Large pelvic mass Fistula Ovarian recurrence in vagina Large Cervical Ca Vaginal involvement Sidewall involvement Bladder involvement Vaginal Cancer (>5mm thickness) Vulvar Cancer with vaginal extension Urethral Cancer, Bladder Cancer Applicators for A INTERSTITIAL B Tandem and Ring Tandem use improves OS C Tandem and Ovoids 3

Applicators: Syed Template Applicators: Individualize Selection Syed Circular formation Martinez Angled insertion to cover parametria No obturator/not for vaginal ca Ring or ovoids with needles Short needles to cover Not for extensive vaginal ca Cylinder with catheters Free hand Customized design Fleming et al. Obst Gyn 55(4):525-530, 1980 Template and Catheter Placement Ultrasound IteraXve InserXon Technique: or Serial 1.25-2.5 mm slice thickness Stitch at vaginal apex for countertraction Stitch template Workflow: Diagnostic series: T2 a/s/c T1 contrast DWI Intra-procedure: bssfp Sagittal bssfp Axial T2 axial Final series: T2 axial/sag/cor for planning 1.6mm thick cover template Stylets, change to Radioque markers for imaging Number steri-strips, attach clockwise U/S and I lesion correlation Dose Distributions Cylinder For postop endo ca Interstitial For gross disease Trans rectal Mahantshetty U et al. Radiotherapy and Oncology. 2012. Schmid MP et al. Strahlenther Onkol. 2013. 4

To safely use HDR, need 3D imaging Opera)ng Room Laparoscopic Guidance Image with Xray, or awer inser)on Suite Fluoroscopy, Ultrasound,, I Simulator with anesthesia Itera)ve Imaging Interven)onal with anesthesia Diagnos)c Radiology Normal Xssue rouxnely contoured by respondents who have 3D imaging available a_er applicator placement X-ray versus brachytherapy after chemoradiation # Imaging During BT Local control (%) Disease specific Survival (%) Overall Survival (%) Grade 3-4 Toxicity 118 Xray 74 55 65 22.7 117 78.5* 60 74 2.6 Advantage of Image-based intersxxal brachytherapy for vaginal cancer / Xray / Xray / Xray Charra-Brunaud et al. STIC Radioth Oncol 2012 25 pt Xray, 31, 16 DFI MV HR IBBT 0.24 (0.07-0.73) Chemo, HDR and IBBT reduced relapse Manuel et al. Radiotherapy and Oncology 2016 Sep;120(3):486-492 Interstitial in Cervical Cancer First author # Stage Dose LC Imaging Eisbruch 11 IIB-IVA 68-73 Gy 64% Ishohashi 25 IB2-IVA - 68% Sharma 42 IIB-IVA - 62% Kannan 47 IIB-IVA 75 68% Wang 20 IIB-IIIB 87 90% Lee 17 IIB-IVA 77 88% Pinn- Bingham 116 IB1-IVA 98 85% Viswanathan 6 IIB-IVB 85 83% and Yoshida 29 IIB-IVB - 93% Kamran 56 IIB-IVA 80Gy 97% 87% vs vs Interstitial Cervical Ca Kamran et al ABS 2016 5

-based brachytherapy data -based HDR brachytherapy Tumor size < 4cm Tumor size > 4cm -planned brachytherapy: Change in point A dose versus contouring larger than with contrast clear OAR delineation interface bowel/ cervix difficult visualize GTV Bladder HR-V Still treat entire uterus 3% decrease in point A dose Tumors < 4cm 4% decrease in point A dose Tumors > 4cm Rectum Int J Radiat Oncol Biol Phys 2007 Jun 1;68(2):491-8 Cho et al. Gyn Onc epub 2016 RTOG Consensus contour (red) Parametrial extension, good response (red) vs. (blue) IJROBP 2014; 90(2):320-8 IJROBP 2014; 90(2):320-8 6

Large tumor, poor response (red) vs. (blue) No parametrial extension Complete response (red) vs. (blue) www.nrgoncology.org/resources/contouring-atlases/ GYNCervical- Parametrial extension defines whether differs from contours No parametrial extension=identical contours Poor parametrial response = similar contours Good parametrial response = largest discrepancy in contours 7